---
figid: PMC9672595__11523_2022_925_Fig1_HTML
pmcid: PMC9672595
image_filename: 11523_2022_925_Fig1_HTML.jpg
figure_link: /pmc/articles/PMC9672595/figure/Fig1/
number: Fig. 1
figure_title: ''
caption: FDA-approved therapies for advanced PC. Initial years of approval in the
  USA are shown. aApproved for the treatment of adult and pediatric patients with
  unresectable or metastatic, microsatellite instability-high, or deficient mismatch
  repair solid tumors (including PC) that have progressed following prior treatment
  and for whom no satisfactory alternative treatment options exist. bApproved for
  the treatment of adult patients with mismatch repair–deficient recurrent or advanced
  solid tumors (including PC), as determined by an FDA-approved test, that have progressed
  on or following prior treatment and for whom no satisfactory alternative treatment
  options exist. cApproved for the treatment of adult patients with prostate-specific
  membrane antigen–positive mCRPC who have been treated with androgen receptor pathway
  inhibition and taxane-based chemotherapy. CRPC castrate-resistant prostate cancer,
  FDA Food and Drug Administration, 177Lu lutetium-177, mCRPC metastatic castrate-resistant
  prostate cancer, mHSPC metastatic hormone-sensitive prostate cancer, nmCRPC nonmetastatic
  castrate-resistant prostate cancer, PARP poly (ADP-ribose) polymerase, PC prostate
  cancer
article_title: Addressing Challenges and Controversies in the Management of Prostate
  Cancer with Multidisciplinary Teams.
citation: Neal D. Shore, et al. Target Oncol. 2022 Nov 18 ;17(6):709-725.
year: '2022'

doi: 10.1007/s11523-022-00925-7
journal_title: Targeted Oncology
journal_nlm_ta: Target Oncol
publisher_name: Springer International Publishing

keywords:
---
